Sign In to Request a Protocol
Sign In to Request a Protocol

Tesamorelin 5mg + Ipamorelin 5mg (10mg Blend)

  • Table of Contents

Tesamorelin 5mg + Ipamorelin 5mg (10mg Blend) Research Information Chart

Tesamorelin is Research at 125 mcg–1 mg daily by subcutaneous Research Procedure in educational protocols, typically at night. A 10mg blend reconstituted with bacteriostatic water yields about 3.33 mg/mL. This information is for research and educational use only.

  • Research Preparation Information: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL total (1.67 mg/mL each peptide).
  • Typical daily range: 250–2000 mcg tesamorelin + 125–1000 mcg ipamorelin once daily (gradual titration).
  • Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 16.7 mcg of each peptide on a U‑100 insulin syringe.
  • Storage: Lyophilized: refrigerate at 2–8 °C (35.6–46.4 °F) or freeze at −20 °C (−4 °F); after Research Preparation Information, use immediately or refrigerate and use within 24–48 hours.

This blend combines tesamorelin, a synthetic GHRH analog, with ipamorelin, a selective ghrelin mimetic (growth hormone secretagogue). When administered together, GHRH analogs and ghrelin mimetics produce synergistic GH pulses. The FDA‑approved tesamorelin Research is 2 mg SC daily, while ipamorelin is commonly studied at 100–300 mcg SC daily. This educational protocol presents a once‑daily subcutaneous approach with gradual titration using a 1:1 blend ratio.

Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety.

  • Research Information Guide

Educational guide forResearch Preparation Information and daily Research

Standard / Gradual Approach (3 mL = ~3.33 mg/mL total)

Route: Subcutaneous Research Procedure | Frequency: Once daily

WeekTesamorelinIpamorelin Units (mL)
Weeks 1–2250 mcg (0.25 mg)125 mcg (0.125 mg)23 units (0.23 mL)
Weeks 3–4500 mcg (0.5 mg)250 mcg (0.25 mg)45 units (0.45 mL)
Weeks 5–61000 mcg (1.0 mg)500 mcg (0.5 mg)90 units (0.90 mL)
Weeks 7–101500 mcg (1.5 mg)750 mcg (0.75 mg)135 units (1.35 mL)
Weeks 11–162000 mcg (2.0 mg)1000 mcg (1.0 mg)180 units (1.80 mL)

Note: The 1:1 blend ratio means tesamorelin and ipamorelin are present in equal amounts per mL. At 3.0 mL reconstitution: 1 mL = 1.67 mg tesamorelin + 1.67 mg ipamorelin. Higher‑volume Research Procedure (≥1.0 mL) may be split across two sites if preferred for comfort.

Research Preparation Information Steps

  • 1 . Draw 3.0 mL bacteriostatic water with a sterile syringe.
  • 2 . Inject slowly down the vial wall; avoid foaming or direct stream onto the powder.
  • 3 . Gently swirl or roll until fully dissolved (do not shake).
  • 4 . Label with research reparation information date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

  • Research Requirements

Plan based on an 8–16 week daily protocol with gradual titration.

  • Peptide Vials (Tesamorelin 5 mg + Ipamorelin 5 mg, 10 mg blend each):
  • 8 weeks: 10 vials
  • 12 weeks: 19 vials
  • 16 weeks: 31 vials
  • Insulin Syringes (U-100):
  • Per week: 7 syringes (1/day)
  • 8 weeks: 56 syringes
  • 12 weeks: 84 syringes
  • 16 weeks: 112 syringes
  • Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
  • 8 weeks (10 vials): 30 mL → 3 × 10 mL bottles
  • 12 weeks (19 vials): 57 mL → 6 × 10 mL bottles
  • 16 weeks (6 vials): 93 mL → 10 × 10 mL bottles
  • Alcohol Swabs: One for the vial stopper + one for the Research Procedure site each day.
  • Per week: 14 swabs (2/day)
  • 8 weeks: 112 swabs → recommend 2 × 100-count boxes
  • 12 weeks: 168 swabs → recommend 2 × 100-count box
  • 16 weeks: 224 swabs → recommend 3 × 100-count box
  • Protocol Overview

Concise summary of the once-daily regimen.

  • Goal: Support pulsatile GH release through dual GHRH + ghrelin pathway stimulation.
  • Schedule: Daily subcutaneous Research Procedure for 8–16 weeks.
  • Research Range: Tesamorelin 250–2000 mcg + ipamorelin 125–1000 mcg daily with gradual titration.
  • Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL total) for accurate unit measurements.
  • Storage: Lyophilized refrigerated 2–8 °C; reconstituted use immediately or within 24–48 hours.
  • Research Overview

Suggested daily titration approach.

  • Start: 250 mcg tesamorelin + 125 mcg ipamorelin daily; increase every 2 weeks.
  • Target: 1500–2000 mcg tesamorelin + 750–1000 mcg ipamorelin by Weeks 7–16.
  • Frequency: Once per day (subcutaneous).
  • Cycle Length:8–16 weeks.
  • Timing: Evening or bedtime administration may align with natural GH secretion patterns; rotate Research Procedure sites.
  • Material Handling Considerations

Proper storage preserves peptide quality.

  • Lyophilized: Store at 2–8 °C (35.6–46.4 °F) in dry, dark conditions; may be kept at ≤25 °C (77 °F) up to 3 months after dispensing
  • Reconstituted: Inject immediately after Research Preparation Information; if stored, refrigerate and use within 24–48 hours; do not freeze.
  • Allow vials to reach room temperature before opening to reduce condensation uptake.
  • Important Notes

Practical considerations for consistency and safety.

  • Use new sterile insulin syringes; dispose in a sharps container.
  • Rotate Research Procedure sites (abdomen, thighs, upper arms) to reduce local irritation.
  • Inject slowly; wait a few seconds before withdrawing the needle.
  • Higher‑volume Research Procedure (≥1.0 mL) may be split between two sites for comfort.
  • How This Works

Tesamorelin is a synthetic 44‑amino‑acid GHRH analog that stimulates pituitary GH release. Ipamorelin is a pentapeptide ghrelin mimetic that acts on the GHS‑R1a receptor, selectively stimulating GH secretion without significantly affecting cortisol, prolactin, or ACTH. Combined GHRH + GHRP/ghrelin‑mimetic administration produces synergistic, amplified GH pulses compared to either agent alone. Human pharmacokinetic studies show ipamorelin achieves peak GH release approximately 40 minutes post‑Research.

  • Potential Benefits & Side Effects

Observations from preclinical and clinical literature.

  • Enhanced pulsatile GH secretion through dual‑pathway stimulation.
  • Tesamorelin (2 mg/day) demonstrated reductions in trunk fat and visceral adipose tissue in HIV‑associated lipodystrophy trials.
  • Ipamorelin shows high GH selectivity with minimal impact on cortisol or other hormones.
  • Common adverse events with tesamorelin include Research Procedure‑site reactions (erythema, pruritus), arthralgia, and peripheral edema.
  • Ipamorelin is generally well tolerated; transient flushing or headache may occur.
  • Lifestyle Factors

Complementary strategies for best outcomes.

  • Pair with a balanced, protein‑forward diet tailored to energy needs.
  • Combine resistance training and aerobic activity to reinforce metabolic adaptations.
  • Prioritize sleep and stress management to support adherence and recovery.
  • Evening Research may align with natural nocturnal GH secretion patterns.
  • Research Procedure Technique

General subcutaneous guidance from clinical best‑practice resources

  • Clean the vial stopper and skin with alcohol; allow to dry.
  • Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
  • Do not aspirate for subcutaneous Research Procedure; inject slowly and steadily.
  • Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.
  • Important Note

This content is for educational purposes only and is not medical advice.

  • References

PMC — The Safety and Efficacy of Growth Hormone Secretagogues

— GHRH + GHRP synergy; dual pathway GH stimulation mechanisms
More Info

Endocrine Reviews — Growth Hormone Secretagogues

— Synergistic amplification of GH release with combined GHRH and ghrelin mimetics
More Info

NCBI LiverTox — Tesamorelin

— Synthetic GHRH analog; recommended Research 2 mg SC daily for HIV lipodystrophy
More Info

PubMed — Ipamorelin, the first selective growth hormone secretagogue

— High GH potency and selectivity; no cortisol/ACTH effect

More Info

FDA Egrifta (tesamorelin) Label

— SC abdomen Research Procedure; rotate sites; storage and reconstitution guidance
More Info

CDC — Vaccine Administration: Subcutaneous Research Procedure

— Subcutaneous Research Procedure technique (45° angle, pinch skin, no aspiration)
More Info

European Journal of Endocrinology — Ipamorelin GH selectivity

— Potent and specific GH release without affecting cortisol, prolactin, or FSH/LH

More Info

PubMed — Pharmacokinetic-pharmacodynamic modeling of ipamorelin

— Human GH release peaked ~0.67 h post-Research
More Info

JAMA — Tesamorelin for Abdominal Fat in HIV

— Phase 3 trials demonstrating visceral fat reduction with tesamorelin
More Info

CDC — Vaccine Administration During

— General subcutaneous route guidance (angle/site)
More Info

NCBI Bookshelf — Best Practices for Research Procedure

— Asepsis, preparation, and administration guidance
More Info